在流感爆发期间进行的一项双盲研究中对1-β-D-呋喃核糖基-1,2,4-三唑-3-甲酰胺（利巴韦林）的临床评估。

Clinical evaluation of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) in a double-blind study during an outbreak of influenza.

作者信息

Salido-Rengell F, Nasser-Quinones H, Briseno-Garcia B

出版信息

Ann N Y Acad Sci. 1977 Mar 4;284:272-7. doi: 10.1111/j.1749-6632.1977.tb21960.x.

DOI:10.1111/j.1749-6632.1977.tb21960.x

Abstract

1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) at a dosage of 300 mg/day, or disguised placebo was administered to patients in a closed population during an epidemic outbreak of influenza in Mexico City. Treatment consisted of capsules given three times daily for 5 days beginning with first signs of disease. The study was conducted in a double-blind fashion. Clinical manifestations of the disease, as well as in titer of recoverable virus and in specific serum antibody titer were significantly reduced in the ribavirin-treated group. None of the individuals in the study had any sign of toxic effects attributable to the drug. In the study, 21 patients received the drug and 24 received placebo.

摘要

在墨西哥城流感疫情爆发期间，对封闭人群中的患者给予1-β-D-呋喃核糖基-1,2,4-三唑-3-甲酰胺（利巴韦林），剂量为300毫克/天，或伪装成安慰剂。治疗从疾病的最初症状开始，采用胶囊剂，每日三次，共5天。该研究采用双盲方式进行。利巴韦林治疗组的疾病临床表现、可恢复病毒滴度和特异性血清抗体滴度均显著降低。研究中的个体均未出现任何可归因于该药物的毒性作用迹象。该研究中，21名患者接受了药物治疗，24名患者接受了安慰剂治疗。